Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
SURPASS-CVOT is unique, in that it compares the dual incretin agonist with a GLP-1 RA that has been shown to have cardiovascular benefit in people with type 2 diabetes and high risk ASCVD
As GLP-1 medications, including weight loss medications like Ozempic and Wegovy, become more common for weight management and diabetes, ensuring safe delivery is a top priority for specialty pharmacies
It activates GLP-1, GIP, and glucagon receptors at the same time
Clinical oversight is provided by Dr
US$ 22.93
US$ 20.09
US$ 28.98
US$ 21.94
US$ 23.99
